A director at Protagonist Therapeutics Inc sold after exercising options 28,000 shares at 83.130USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...
Figure 1 - Rapid Response from Rusfertide TreatmentSource: Company data; Wedbush researchFigure 2 - Ph3 52-Week Data Show Durable Response from Rusfertide TreatmentSource: Company dataFigure 3 - Design of the REVIVE and THRIVE StudiesSource: Company data; Wedbush researchFigure 4 - Long-Term Rusfer
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.